Novartis Recalls Sandimmune Oral Solution

RTTNews | 363 days ago
Novartis Recalls Sandimmune Oral Solution

(RTTNews) - Swiss drug major Novartis AG is recalling two lots of its Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL at the consumer level in the US, the U.S. Food and Drug Administration said.

The recall was initiated after crystal formation was observed in some bottles, which could potentially result in incorrect dosing.

Sandimmune Oral Solution is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. The drug may also be used to treat chronic rejection in patients previously treated with other immunosuppressive agents.

The affected drugs were packaged in 50 mL bottles, with lot numbers and expiration dates of FX001500 (expiration date 09/2024) and FX001582 (expiration date 09/2024) NDC 0078-0110-22.

These lots were only distributed to wholesalers across the US, beginning in January 2022 and September 2022, respectively.

According to the agency, crystallization of cyclosporine in Sandimmune Oral Solution is likely to result in non-uniform distribution of the cyclosporine in the product, resulting in under-dosing or over-dosing.

Under-dosing may result in lower exposures and decrease in efficacy which could ultimately lead to graft rejection and graft loss in transplant patients, while over-dosage may manifest itself as cyclosporine toxicity in the long term if over exposure continues.

The issue was identified during an investigation of crystallization in a different lot of Sandimmune Oral Solution. No other Sandimmune formulations are impacted.

Novartis has not received any reports of adverse events related to the recalled product to date.

The company is urging distributors, retailers, and consumers to return the product, and to inform health care providers who have prescribed the drug.

Novartis earlier in September had recalled one lot of its Sandimmune Oral Solution citing the same issue of crystal formation. The affected lot number was FX001691 with expiration date of December 2025.

For More Such Health News, visit rttnews.com

read more
Novartis Lifts FY24 Outlook After Q3 Beats Market; But Stock Down

Novartis Lifts FY24 Outlook After Q3 Beats Market; But Stock Down

Swiss drug major Novartis AG on Tuesday raised its core operating income and sales guidance for fiscal 2024 after reporting significantly higher profit in its third quarter, driven by sales growth in key drugs. The third-quarter core earnings and topline beat market estimates. Meanwhile, the shares were losing around 3 percent in the Swiss trading as well as in early morning trading on the NYSE.
RTTNews | 27 days ago
Novartis Q1 Profit Tops Market, Lifts FY24 View, Proposes New Chair; Stock Up

Novartis Q1 Profit Tops Market, Lifts FY24 View, Proposes New Chair; Stock Up

Novartis AG's shares were gaining more than 4 percent in Switzerland and more than 5 percent in pre-market activity on the NYSE after the Swiss drug major reported Tuesday higher first-quarter profit, above market estimates, with strong sales growth. The company also raised its fiscal 2024 outlook for growth in sales and core operating income.
RTTNews | 216 days ago
Novartis Stock Down As Q4 Core EPS Miss Estimates; Sees Growth In FY24

Novartis Stock Down As Q4 Core EPS Miss Estimates; Sees Growth In FY24

Shares of Novartis AG were losing more than 4 percent in the morning trading on the Switzerland exchange as well as in pre-market activity on the NYSE after the Swiss drug major's core earnings in the fourth quarter missed market estimates. On a reported basis, net profit surged on hefty income from discontinued operations related to Sandoz Group AG spin-off, as well as higher sales.
RTTNews | 299 days ago
Novartis Recalls One Lot Of Sandimmune Oral Solution 100 Mg/mL

Novartis Recalls One Lot Of Sandimmune Oral Solution 100 Mg/mL

Novartis AG (NVS) announced Monday it has recalled one lot of its Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the US due to crystal formation observed in some bottles. The company added that no other Sandimmune formulations are impacted.
RTTNews | 441 days ago
Novartis Lifts FY23 View As Q2 Results Top Market, Initiates $15 Bln Buyback; Stock Up

Novartis Lifts FY23 View As Q2 Results Top Market, Initiates $15 Bln Buyback; Stock Up

Shares of Novartis AG were gaining around 4 percent in the morning trading in Switzerland as well as in pre-market activity on the NYSE after the drug major raised its fiscal 2023 outlook on Tuesday after reporting higher second-quarter results. Core earnings and top line beat market estimates. Further, the company announced up to $15 billion share buyback to be completed by year-end 2025.
RTTNews | 496 days ago
Novartis Says FDA Approves Expanded Use For Leqvio

Novartis Says FDA Approves Expanded Use For Leqvio

Novartis AG (NVS) announced Monday that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy.
RTTNews | 504 days ago
Novartis Gets Positive CHMP Opinion For Entresto For Pediatric Heart Failure

Novartis Gets Positive CHMP Opinion For Entresto For Pediatric Heart Failure

Novartis AG (NVS) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Entresto (sacubitril/valsartan) for a new indication to treat symptomatic chronic heart failure with left ventricular systolic dysfunction in pediatric patients aged from 1 to <18 years.
RTTNews | 605 days ago